惡性間皮癌市場規模、佔有率和成長分析（按上市藥物、後期研發藥物和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，惡性間皮癌市場規模將達到 1.7197 億美元，到 2025 年將達到 1.8178 億美元，到 2033 年將達到 2.8323 億美元，在預測期（2026-2033 年）內複合年成長率為 5.7%。

惡性間皮癌患者權益倡導團體和支持網路的顯著影響力凸顯了它們在對抗這種癌症中的關鍵作用。這些組織透過提高公眾意識和促進早期診斷，改善了患者的治療效果。它們致力於倡導、教育和提高公眾意識，這對於改善患者照護、確保間皮瘤患者在整個治療過程中獲得所需的支持和資源至關重要。因此，這些網路不僅賦予患者力量，還促進了相互理解和支持的社區建設，強調了在應對這種侵襲性疾病帶來的挑戰時，合作的重要性。這些團體的積極參與有助於為患者創造一個更資訊豐富、更支持性的環境，這對於應對間皮瘤治療和護理的複雜性至關重要。

惡性間皮癌市場促進因素

診斷技術的進步顯著推動了惡性間皮癌市場的成長。用於檢測這種癌症的技術和工具日益精進，使得病例的識別更加精進的。此外，醫療專業人員和公眾對該疾病的認知不斷提高，也促進了早期發現和診斷。因此，越來越多的病例在早期階段被發現和診斷，這不僅增加了對治療方法的需求，也凸顯了該領域持續研發的重要性。

限制惡性間皮癌市場的因素

惡性間皮癌的特徵是潛伏期長，從最初接觸石棉到出現症狀可能長達數十年。如此長的潛伏期嚴重阻礙了疾病的早期發現和高危險群的適當治療。由於症狀出現延遲，確診時疾病往往已發展到晚期，這不僅使治療方案複雜化，也降低了介入成功的幾率。因此，疾病的長期性嚴重阻礙因素了惡性間皮癌市場的發展，影響著患者的治療效果和醫療保健策略。

惡性間皮癌市場趨勢

惡性間皮癌市場正受到人口老化的顯著影響，這種主要影響老年人的侵襲性癌症的發生率不斷上升。隨著全球人口壽命的延長，預計間皮瘤確診患者人數將急劇增加。此外，疾病的潛伏期較長，症狀通常在接觸石棉數十年後才出現，這使得先進的診斷和治療性介入更加迫切。因此，製藥公司和醫療保健機構正致力於開發創新的治療方案和支援系統，以滿足此細分但重要的腫瘤市場日益成長的需求。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球惡性間皮癌市場規模（依上市藥物及複合年成長率分類）（2026-2033 年）

• 作用機制
• 監管狀態
• 臨床試驗結果
• 藥物採納情形及市場表現

全球惡性間皮癌市場規模（依後期研發藥物及複合年成長率分類）（2026-2033 年）

• 作用機制
• 監管狀態
• 臨床試驗結果
• 藥物採納情形及市場表現

全球惡性間皮癌市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AstraZeneca（United Kingdom）
• Bristol-Myers Squibb（United States）
• Merck & Co., Inc.（United States）
• Novartis International AG（Switzerland）
• Pfizer Inc.（United States）
• Sanofi SA（France）
• Eli Lilly and Company（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• F. Hoffmann-La Roche AG（Switzerland）
• Boehringer Ingelheim GmbH（Germany）
• Mylan NV（United States）
• Fresenius Kabi AG（Germany）
• Sun Pharmaceutical Industries Ltd.（India）
• Corden Pharma GmbH（Germany）
• Concordia International Corp.（Canada）
• Kyowa Hakko Kirin Co., Ltd.（Japan）
• Polaris Pharmaceuticals, Inc.（United States）
• Nichi-Iko Pharmaceutical Co., Ltd.（Japan）

結論與建議

Malignant Mesothelioma Market size was valued at USD 171.97 Million in 2024 and is poised to grow from USD 181.78 Million in 2025 to USD 283.23 Million by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The significant impact of malignant mesothelioma patient advocacy groups and support networks underscores their crucial role in combating this cancer. These organizations enhance awareness and promote early diagnosis, thereby improving outcomes for affected individuals. Their dedicated efforts in advocacy, education, and outreach are vital in improving patient care, ensuring that those impacted by mesothelioma receive the necessary support and resources for their journey. As a result, these networks not only empower patients but also foster a community of understanding and assistance, highlighting the importance of collaborative efforts in addressing the challenges posed by this aggressive disease. Enhanced engagement from these groups contributes to better-informed patients and a supportive environment, essential for navigating the complexities of mesothelioma treatment and care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malignant Mesothelioma Market Segments Analysis

Global Malignant Mesothelioma Market is segmented by In-Market Drugs, Late-Stage Pipeline Drugs and region. Based on In-Market Drugs, the market is segmented into Mechanism of Action, Regulatory Status, Clinical Trial Results and Drug Uptake and Market Performance. Based on Late-Stage Pipeline Drugs, the market is segmented into Mechanism of Action, Regulatory Status, Clinical Trial Results and Drug Uptake and Market Performance. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Malignant Mesothelioma Market

The increasing advancements in diagnostic techniques significantly contribute to the growth of the malignant mesothelioma market. Enhanced methods and tools for detecting this particular type of cancer have seen remarkable improvements, facilitating more accurate identification of cases. Furthermore, rising awareness among healthcare professionals and the general public about the disease has fostered earlier detection and diagnosis. Consequently, a greater number of cases are being recognized and diagnosed at an initial stage, which not only elevates the demand for treatment options but also emphasizes the importance of ongoing research and development in this area.

Restraints in the Malignant Mesothelioma Market

Malignant mesothelioma is marked by an extended latency period, often lasting several decades from the initial exposure to asbestos to the onset of symptoms. This lengthy interval creates significant obstacles, as it hinders the ability to identify the disease early and implement timely treatment for those at risk. The delay in symptom manifestation can result in advanced disease stages by the time diagnosis occurs, complicating the therapeutic approach and reducing the chances of successful intervention. Consequently, the protracted nature of this condition serves as a considerable restraint within the market for malignant mesothelioma, impacting both patient outcomes and healthcare strategies.

Market Trends of the Malignant Mesothelioma Market

The malignant mesothelioma market is notably influenced by the aging population, resulting in heightened incidence rates of this aggressive cancer primarily affecting older adults. With a significant portion of the global demographic experiencing longer life expectancies, the number of individuals diagnosed with mesothelioma is predicted to surge. This trend is compounded by the disease's long latency period, where symptoms may emerge decades after asbestos exposure, intensifying the urgency for advanced diagnostic and therapeutic interventions. Consequently, pharmaceutical companies and healthcare providers are focusing on developing innovative treatment options and support systems to address the rising demand within this niche yet critical oncology market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Malignant Mesothelioma Market Size by In-Market Drugs & CAGR (2026-2033)

• Market Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Global Malignant Mesothelioma Market Size by Late-Stage Pipeline Drugs & CAGR (2026-2033)

• Market Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Global Malignant Mesothelioma Market Size & CAGR (2026-2033)

• North America (In-Market Drugs, Late-Stage Pipeline Drugs)
  • US
  • Canada
• Europe (In-Market Drugs, Late-Stage Pipeline Drugs)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (In-Market Drugs, Late-Stage Pipeline Drugs)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (In-Market Drugs, Late-Stage Pipeline Drugs)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (In-Market Drugs, Late-Stage Pipeline Drugs)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corden Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concordia International Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nichi-Iko Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations